SSY Group Limited — Earnings Release 2016

Apr 29, 2016

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [214 x 47] intentionally omitted <==

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

ANNOUNCEMENT OF TURNOVER AND GROSS PROFIT INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2016

The Company announces the turnover and gross profit information, which has not been reviewed by its auditor, for the three months ended 31 March 2016.

The board of directors (the “Board”) of SSY Group Limited (the “Company”) announces the financial information of turnover and gross profit of the Company and its subsidiaries (together, the “Group”) for the three months ended 31 March 2016 based on its management accounts which has not been reviewed by the auditor of the Company.

Majority of the Group’s sales are conducted in the PRC and are denominated in Renminbi, which depreciated by approximately 5.7% when translated into Hong Kong dollars for the three months ended 31 March 2016 as compared with that for the same period of 2015. Nevertheless, turnover of the Group for the three months ended 31 March 2016 increased by 5.72% as compared with the same period of 2015 to HK$515 million.

Gross profit margin of the Group for the three months ended 31 March 2016 was 47.8%, representing a drop of 0.9% percentage point from 48.7% for the same period of 2015 mainly due to a lower gross profit margin of the new business segment in medical materials as compared with that of the intravenous infusion solution.

Among the abovementioned turnover of the Group, sales of intravenous infusion solution (including the subcontracting products) for the three months ended 31 March 2016 was HK$451 million. Among which, sales of non-PVC soft bag and upright soft bag infusion solution was HK$298 million, representing 66.0% of the sales of intravenous infusion solution and an increase of 2.1% as compared with sales for the same period of 2015; sales of PP plastic bottle infusion solution was HK$114 million, representing 25.3% of the sales of intravenous infusion solution and an increase of 1.4% as compared with sales for the same period of 2015.

— 1 —

Shareholders and potential investors of the Company are advised to exercise caution in dealing in the shares of the Company.

On behalf of the Board Chow Hing Yeung Company Secretary

Hong Kong, 29 April 2016

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.

— 2 —